Epilepsy Device (VNS/RNS) Insurance Denied: Appeal
VNS, RNS, or DBS for epilepsy denied by insurance? Appeal using drug-resistant epilepsy documentation, FDA indications, and AES guidelines. Guide inside.
For the one-third of epilepsy patients whose seizures cannot be controlled by antiseizure medications (ASMs), neurostimulation devices offer a lifeline. The three main FDA-approved devices for drug-resistant epilepsy — Vagus Nerve Stimulator (VNS), Responsive Neurostimulator (RNS, brand name NeuroPace), and Deep Brain Stimulator (DBS) — can significantly reduce seizure frequency, improve quality of life, and in some cases achieve seizure freedom. Insurance denials for these devices are common and represent a serious obstacle to life-changing care.
The Three Major Epilepsy Neurostimulation Devices
Vagus Nerve Stimulator (VNS) — a pacemaker-like device surgically implanted in the chest that delivers electrical impulses to the brain via the left vagus nerve. FDA-approved since 1997 for adjunctive treatment of drug-resistant focal epilepsy in patients 4 years and older who are not candidates for resective surgery or who have not benefited from resective surgery. The LivaNova Sentiva (formerly Cyberonics) is the primary commercial device.
Responsive Neurostimulator (RNS, NeuroPace) — a closed-loop device implanted directly in the skull that continuously monitors brain activity and delivers targeted electrical stimulation when it detects abnormal patterns. FDA-approved for adults (18+) with drug-resistant focal epilepsy from up to two seizure foci who are not candidates for resective surgery or who have not benefited from it. More expensive than VNS and more specialized.
Deep Brain Stimulator (DBS) — Medtronic's Percept PC and related systems are FDA-approved for drug-resistant epilepsy in patients 18+ as adjunctive therapy for drug-resistant focal epilepsy. DBS targets the anterior nucleus of the thalamus.
Why Insurers Deny Epilepsy Neurostimulation Devices
Drug-resistant epilepsy not adequately documented. Most payer criteria require documentation that the patient has tried and failed at least 2–3 appropriately chosen ASMs at therapeutic doses and adequate duration. "Failure" means persistent seizures despite adequate drug levels, or intolerable side effects at effective doses. If the medication trial history isn't clearly documented, the insurer may deny.
Surgical candidacy not established. VNS and RNS labeling specify patients who are "not candidates for resective surgery or who have not benefited from it." Payers may require documentation of a comprehensive epilepsy surgery evaluation — including video-EEG monitoring, brain MRI, neuropsychological testing, and multidisciplinary epilepsy team review — to establish non-candidacy for resection. If this evaluation hasn't been performed at a comprehensive epilepsy center, insurers may deny on the grounds that surgery candidacy hasn't been ruled out.
Age restrictions. VNS is approved from age 4; RNS and DBS are approved for adults 18+. Pediatric patients may face additional scrutiny.
Off-label applications. While VNS has some evidence for generalized epilepsy syndromes (Lennox-Gastaut syndrome, among others), payers may deny off-label uses that fall outside the strict FDA focal epilepsy indication. RNS has emerging evidence for use in more than two foci and for generalized epilepsy, but coverage for these uses may be limited.
Device cost. VNS systems cost approximately $15,000–30,000; RNS and DBS systems are more expensive. This cost — combined with neurosurgeon fees and OR time — motivates aggressive Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization requirements.
Building Your Clinical Appeal
Document Drug-Resistant Epilepsy
Create a comprehensive medication history: for each ASM tried, list the drug name, maximum dose achieved, duration, serum drug levels if monitored, and reason for discontinuation (lack of seizure control, adverse effects, or allergy). The ILAE (International League Against Epilepsy) defines drug-resistant epilepsy as failure of adequate trials of two tolerated, appropriately chosen, and used ASMs — whether as monotherapy or combination therapy — to achieve sustained seizure freedom.
ClaimBack generates a professional appeal letter in 3 minutes — citing real insurance regulations for your country. Get your free analysis →
Two failed ASM trials satisfies the clinical definition of drug-resistant epilepsy. Document each trial explicitly and include this ILAE definition in your appeal.
Submit Epilepsy Surgery Evaluation Records
If a comprehensive epilepsy center evaluation was performed to assess surgical candidacy, submit the multidisciplinary team's conclusions. If the evaluation concluded that the patient is not a candidate for resective surgery (due to eloquent cortex involvement, bilateral or multifocal onset, or other reasons), this directly satisfies a key coverage criterion.
If an evaluation hasn't been performed, consider requesting one — both to optimize clinical care and to satisfy payer requirements. A letter from a comprehensive epilepsy center confirming non-surgical candidacy is powerful evidence.
Seizure Frequency and Impact Documentation
Document current seizure frequency (weekly, monthly), seizure type and severity, injury history from seizures (falls, burns, head trauma, status epilepticus), driving restrictions, employment impacts, and quality-of-life impairment. A seizure diary covering at least 3 months is ideal. High-frequency or severe seizures strengthen the medical necessity argument.
Cite AES and ILAE Guidelines
The American Epilepsy Society (AES) and ILAE endorse VNS, RNS, and DBS as evidence-based adjunctive therapies for drug-resistant focal epilepsy. The AES has position statements on neurostimulation for epilepsy. Cite these in your appeal and have your epileptologist or neurologist attest that your patient meets guideline criteria.
Peer-to-Peer Review
Epilepsy device denials often hinge on clinical nuance. Request a peer-to-peer call between your epileptologist (ideally from a comprehensive epilepsy center) and the insurer's medical reviewer. Epilepsy device decisions can turn on this conversation — particularly for RNS and DBS, which are newer and less familiar to general medical directors.
Manufacturer Support
- LivaNova (VNS Therapy) — VNS reimbursement support team, appeal letter templates, peer-reviewed evidence library
- NeuroPace (RNS) — dedicated reimbursement team with extensive payer negotiation experience
- Medtronic (DBS) — patient services and prior authorization support
All three manufacturers have experience with insurance denials and provide direct support to patients and epilepsy centers navigating them.
Resources
- Epilepsy Foundation (epilepsy.com) — insurance navigation, advocacy, seizure diary tools
- American Epilepsy Society (AES) — clinical practice guidelines, position papers
- Comprehensive Epilepsy Centers — NAEC-accredited centers (naec-epilepsy.org) are best positioned to document drug-resistant epilepsy and surgical non-candidacy
Epilepsy neurostimulation appeals require clinical depth, but with comprehensive epilepsy center documentation and clear drug-resistance evidence, most cases can be won.
Fight Back With ClaimBack
ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word. Fight your denial at ClaimBack →
Related Reading:
How much did your insurer deny?
Enter your denied claim amount to see what you could recover.
Your insurer is counting on you giving up.
Most people do. Less than 1% of denied claimants ever appeal — even though the majority who do win. ClaimBack was built by people who were denied, who fought back, and who refused to accept "no" from an insurer.
We give you the same appeal arguments that attorneys use — in 3 minutes, for free. Your denial deadline is ticking. Don't let it expire.
Free analysis · No credit card · Takes 3 minutes
Related ClaimBack Guides